Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioAtla (BCAB) Change in Accured Expenses (2020 - 2025)

BioAtla (BCAB) has 6 years of Change in Accured Expenses data on record, last reported at $1.0 million in Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 58.75% year-over-year to $1.0 million; the TTM value through Sep 2025 reached $374000.0, up 102.13%, while the annual FY2024 figure was -$13.5 million, 354.75% down from the prior year.
  • Change in Accured Expenses reached $1.0 million in Q3 2025 per BCAB's latest filing, up from $421000.0 in the prior quarter.
  • Across five years, Change in Accured Expenses topped out at $8.3 million in Q2 2022 and bottomed at -$9.0 million in Q1 2024.
  • Average Change in Accured Expenses over 5 years is $356684.2, with a median of $421000.0 recorded in 2025.
  • Peak YoY movement for Change in Accured Expenses: tumbled 2179.49% in 2022, then skyrocketed 229.51% in 2023.
  • A 5-year view of Change in Accured Expenses shows it stood at -$2.9 million in 2021, then surged by 74.23% to -$735000.0 in 2022, then crashed by 886.26% to -$7.2 million in 2023, then skyrocketed by 56.17% to -$3.2 million in 2024, then skyrocketed by 131.98% to $1.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Accured Expenses were $1.0 million in Q3 2025, $421000.0 in Q2 2025, and $2.1 million in Q1 2025.